Pharming (PHAR) EBT Growth (3y) (2023 - 2026)
Powered by 
Analysis
Pharming (PHAR) EBT Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 6.22% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.16% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 103.79% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 24.03% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 41.79% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 38.36% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -38.56% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 64.03% |
| 10 | Pharming | 794.84 Mn | 635.34 Mn | 141.47 Mn | 49.47% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 49.47% |
| Mar 31, 2026 | 35.63% |
| Dec 31, 2025 | -99.47% |
| Sep 30, 2025 | 10.94% |
| Mar 31, 2025 | -65.08% |
| Dec 31, 2024 | -47.18% |
| Sep 30, 2024 | 27.60% |
| Jun 30, 2024 | -52.37% |
| Mar 31, 2024 | -65.73% |
| Dec 31, 2023 | -31.26% |
| Sep 30, 2023 | 28.25% |